维生素D-24-羟化酶与甲状腺癌的相关性研究进展

doi:10.16352/j.issn.1001-6325.2023.03.490

基础医学与临床 ›› 2023, Vol. 43 ›› Issue (3): 490-494.doi: 10.16352/j.issn.1001-6325.2023.03.490

维生素D-24-羟化酶与甲状腺癌的相关性研究进展

陈施静, 傅菁岚, 邓媛媛, 张颖, 刘慧霞^*

中南大学湘雅医院老年医学内分泌科,中国长沙 410031

收稿日期:2022-05-09 修回日期:2022-11-30 出版日期:2023-03-05 发布日期:2023-02-27
通讯作者: * lhx900@aliyun.com
基金资助:
国家自然科学基金(81873672)

Advances in the study of the correlation between vitamin D-24-hydroxylase and thyroid carcinoma

CHEN Shijing, FU Jinglan, DENG Yuanyuan, ZHANG Ying, LIU Huixia^*

Department of Geriatric Endocrinology, Xiangya Hospital, Central South University, Changsha 410031, China

Received:2022-05-09 Revised:2022-11-30 Online:2023-03-05 Published:2023-02-27
Contact: * lhx900@aliyun.com

摘要/Abstract

摘要： 甲状腺癌(TC)是内分泌系统最常见的恶性肿瘤,维生素D缺乏患者TC患病风险增加。维生素D-24-羟化酶(CYP24A1)是活性维生素D的主要灭活酶,通过灭活1,25-二羟基维生素D₃,抑制维生素D抗增殖效应,促进TC的发生发展。

关键词: 维生素D-24-羟化酶, 甲状腺癌, 维生素D

Abstract: Thyroid carcinoma(TC) is the most common malignant tumor of endocrine system. Patients with vitamin D deficiency have an increased risk of TC. Vitamin D-24-hydroxylase (CYP24A1) is main inactivating enzyme of active vitamin D which may inhibit the antiproliferative effect of vitamin D and promote the development of TC by inactivating 1,25-dihydroxyvitamin D₃.

Key words: vitamin D-24-hydroxylase, thyroid carcinoma, vitamin D

中图分类号:

陈施静, 傅菁岚, 邓媛媛, 张颖, 刘慧霞. 维生素D-24-羟化酶与甲状腺癌的相关性研究进展[J]. 基础医学与临床, 2023, 43(3): 490-494.

CHEN Shijing, FU Jinglan, DENG Yuanyuan, ZHANG Ying, LIU Huixia. Advances in the study of the correlation between vitamin D-24-hydroxylase and thyroid carcinoma[J]. Basic & Clinical Medicine, 2023, 43(3): 490-494.

参考文献

[1]Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin, 2021,71:209-249.
[2]Nireeksha N, Hegde MN, Shetty SS, et al. FOK l vitamin D receptor gene polymorphism and risk of dental caries: a case-control study[J]. Int J Dent, 2022,2022:6601566.doi: 10.1155/2022/6601566.
[3]Alshabrawy AK, Cui Y, Sylvester C, et al. Therapeutic potential of a novel vitamin D(3) oxime analogue, VD1-6, with CYP24A1 enzyme inhibitory activity and negligible vitamin D receptor binding[J]. Biomolecules, 2022,12:960-974.
[4]Annalora AJ, Jozic M, Marcus CB, et al. Alternative splicing of the vitamin D receptor modulates target gene expression and promotes ligand-independent functions[J].TAP, 2019,364:55-67.
[5]Howles SA, Wiberg A, Goldsworthy M, et al. Genetic variants of calcium and vitamin D metabolism in kidney stone disease[J]. Nat Commun, 2019,10:5175-5185.
[6]Penna-Martinez M, Ramos-Lopez E, Stern J, et al. Impaired vitamin D activation and association with CYP24A1 haplotypes in differentiated thyroid carcinoma[J]. Thyroid, 2012,22:709-716.
[7]Balla B, Tobiás B, Kósa JP, et al. Vitamin D-neutraliz-ing CYP24A1 expression, oncogenic mutation states and histological findings of human papillary thyroid cancer[J]. J Endocrinol Invest, 2015,38:313-321.
[8]Clinckspoor I, Hauben E, Verlinden L, et al. Altered expression of key players in vitamin D metabolism and signaling in malignant and benign thyroid tumors[J]. J Histochem Cytochem, 2012,60:502-511.
[9]Kim MJ, Kim D, Koo JS, et al. Vitamin D receptor expression and its clinical significance in papillary thyroid cancer[J]. Technol Cancer Res Treat, 2022,21:15330338221089933.doi: 10.1177/15330338221089933.
[10]Ye Z, Xia X, Xu P, et al. The prognostic implication of the BRAF V600E mutation in papillary thyroid cancer in a Chinese population[J]. Int J Endocrinol, 2022,2022:6562149.doi: 10.1155/2022/6562149.
[11]Boufraqech M, Patel D, Nilubol N, et al. Lysyl oxidase is a key player in BRAF/MAPK pathway-driven thyroid cancer aggressiveness[J]. Thyroid, 2019,29:79-92.
[12]Zou M, Baitei EY, BinEssa HA, et al. Cyp24a1 attenuation limits progression of Braf(V600E)-induced papillary thyroid cancer cells and sensitizes them to BRAF(V600E) inhibitor PLX4720[J]. Cancer Res, 2017,77:2161-2172.
[13]Li T, Zhao N, Lu J, et al. Epigallocatechin gallate (EGCG) suppresses epithelial-mesenchymal transition (EMT) and invasion in anaplastic thyroid carcinoma cells through blocking of TGF-β1/Smad signaling pathways[J]. Bioengineered, 2019,10:282-291.
[14]闫雨生, 于跃利. p-mTOR、p-4EBP1及p-S6K1在甲状腺乳头状癌组织中的表达及临床意义[J]. 系统医学, 2020,5:16-19.
[15]Chen B, Lei S, Yin X, et al. Mitochondrial respiration inhibition suppresses papillary thyroid carcinoma via PI3K/Akt/FoxO1/cyclin D1 pathway[J]. Front Oncol, 2022,12:900444.doi: 10.3389/fonc.2022.900444.
[16]Nasser F, Moussa N, Helmy MW, et al. Dual targeting of Notch and Wnt/β-catenin pathways: potential approach in triple-negative breast cancer treatment[J]. Naunyn Schmiedebergs Arch Pharmacol, 2021,394:481-490.
[17]Wang DP, Tang XZ, Liang QK, et al. microRNA-599 promotes apoptosis and represses proliferation and epithelial-mesenchymal transition of papillary thyroid carcinoma cells via downregulation of Hey2-depentent Notch signal-ing pathway[J]. J Cell Physiol, 2020,235:2492-2505.
[18]Lv J, Feng ZP, Chen FK, et al. M2-like tumor-associated macrophages-secreted Wnt1 and Wnt3a promotes dedifferentiation and metastasis via activating β-catenin pathway in thyroid cancer[J]. Mol Carcinog, 2021,60:25-37.
[19]Hu N, Zhang H. CYP24A1 depletion facilitates the antitumor effect of vitamin D₃ on thyroid cancer cells[J]. Exp Ther Med, 2018,16:2821-2830.
[20]Gao Y, Xiang D, Li W, et al. BRAF(V600E) mutation-responsive miRNA-222-3p promotes metastasis of papillary thyroid cancer cells via snail-induced EMT[J]. Front Endocrinol (Lausanne), 2022,13:843334. doi: 10.3389/fendo.2022.843334.
[21]Li Y, He J, Wang F, et al. Role of MMP-9 in epithelial-mesenchymal transition of thyroid cancer[J]. World J Surg Oncol, 2020,18:181-189.
[22]Biyani M, Yasuda K, Isogai Y, et al. Novel DNA aptamer for CYP24A1 inhibition with enhanced antiproliferative activity in cancer cells[J]. ACS Appl Mater Interfaces, 2022,14:18064-18078.
[23]Karlsson S, Diaz Cruz MA, Faresjö M, et al. Inhibition of CYP27B1 and CYP24 increases the anti-proliferative effects of 25-hydroxyvitamin D(3) in LNCaP cells[J]. Anticancer Res, 2021,41:4733-4740.
[24]Paucarmayta A, Taitz H, Casablanca Y, et al. TGF-β signaling proteins and CYP24A1 may serve as surrogate markers for progesterone calcitriol treatment in ovarian and endometrial cancers of different histological types[J]. Transl Cancer Res, 2019,8:1423-1437.
[25]Azer SM, Vaughan LE, Tebben PJ, et al. 24-Hydroxylase deficiency due to CYP24A1 sequence variants: compari-son with other vitamin D-mediated hypercalcemia disorders[J]. J Endocr Soc, 2021,5:bvab119. doi:10.1210/jendso/bvab119.

维生素D-24-羟化酶与甲状腺癌的相关性研究进展

Advances in the study of the correlation between vitamin D-24-hydroxylase and thyroid carcinoma

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 12

编辑推荐

Metrics

本文评价

[1]	王磊, 伍津津. 女性弥漫性脱发患者的微量营养素分析[J]. 基础医学与临床, 2024, 44(4): 513-517.
[2]	田艳, 马姣姣, 席雪华, 张波. 超声检查评估分化型甲状腺癌颈部转移淋巴结的研究进展[J]. 基础医学与临床, 2023, 43(3): 505-508.
[3]	周美岑, 兰玲, 邓微. RNA结合蛋白在甲状腺癌发病机制中作用的研究进展[J]. 基础医学与临床, 2022, 42(8): 1306-1309.
[4]	傅菁岚, 邓媛媛, 张颖, 章鑫煦, 陈施静, 刘慧霞. 甲状腺癌与糖尿病的相关性研究进展[J]. 基础医学与临床, 2022, 42(4): 667-670.
[5]	谢丽君, 朱高红, 赵继华, 张海波, 王娇. 甲状腺癌肿瘤干细胞的来源和存活途径[J]. 基础医学与临床, 2022, 42(2): 321-324.
[6]	刘亚琪, 郑承红. miR-205通过靶向调控Wnt-5a抑制乳头状甲状腺癌的细胞增殖[J]. 基础医学与临床, 2021, 41(3): 358-363.
[7]	傅松波, 马承旭, 井高静, 赵楠, 汤旭磊, 牟军勤, 常寅龙. 苦参碱对人乳头状甲状腺癌细胞系TPC-1增殖和迁移的影响[J]. 基础医学与临床, 2021, 41(12): 1730-1735.
[8]	辛玉, 贺龙梅, 杨红, 吕红, 谭蓓, 汪红英, 钱家鸣. 1α,25-二羟基维生素D₃抑制人结肠癌细胞系SW480中β-catenin转录活性[J]. 基础医学与临床, 2020, 40(9): 1169-1174.
[9]	曹邓晗, 陈奎生. miR-135b-3p调控XAF1表达影响甲状腺癌细胞的迁移、侵袭和放射增敏性[J]. 基础医学与临床, 2020, 40(6): 790-796.
[10]	曹邓晗, 陈奎生. miR-197-3p调控DMBT1抑制甲状腺癌细胞系增殖、迁移和侵袭[J]. 基础医学与临床, 2020, 40(5): 644-650.
[11]	王丹晨, 尹逸丛, 禹松林, 张瑞丽, 高学慧, 李洪雷, 程歆琦, 邱玲. 性别、年龄和季节对血清25-羟维生素D水平的影响[J]. 基础医学与临床, 2020, 40(2): 151-154.
[12]	张璐刘跃武. 雌激素与甲状腺癌的关系[J]. 基础医学与临床, 2010, 30(7): 782-784.